company background image

Intra-Cellular Therapies NasdaqGS:ITCI Stock Report

Last Price


Market Cap







27 Jun, 2022


Company Financials +
ITCI fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health5/6

ITCI Stock Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.

Intra-Cellular Therapies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intra-Cellular Therapies
Historical stock prices
Current Share PriceUS$57.90
52 Week HighUS$66.00
52 Week LowUS$28.40
1 Month Change-0.65%
3 Month Change-6.75%
1 Year Change43.92%
3 Year Change312.69%
5 Year Change356.99%
Change since IPO479.00%

Recent News & Updates

Jun 18

Intra-Cellular Therapies: A Dramatic Story

Intra-Cellular's atypical antipsychotic CAPLYTA has all the makings of a blockbuster. Now in its initial bipolar launch phase, CAPLYTA is succeeding on all three key leading indicators. Intra-Cellular's financial position is a work in process.

Shareholder Returns

ITCIUS PharmaceuticalsUS Market

Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 12.8% over the past year.

Return vs Market: ITCI exceeded the US Market which returned -18.4% over the past year.

Price Volatility

Is ITCI's price volatile compared to industry and market?
ITCI volatility
ITCI Average Weekly Movement9.7%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ITCI's weekly volatility (10%) has been stable over the past year.

About the Company

2002512Sharon Mates

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.

Intra-Cellular Therapies Fundamentals Summary

How do Intra-Cellular Therapies's earnings and revenue compare to its market cap?
ITCI fundamental statistics
Market CapUS$5.46b
Earnings (TTM)-US$303.50m
Revenue (TTM)US$102.92m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITCI income statement (TTM)
Cost of RevenueUS$112.57m
Gross Profit-US$9.64m
Other ExpensesUS$293.86m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-3.22
Gross Margin-9.37%
Net Profit Margin-294.89%
Debt/Equity Ratio0%

How did ITCI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ITCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ITCI?

Other financial metrics that can be useful for relative valuation.

ITCI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue45.8x
Enterprise Value/EBITDA-15.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does ITCI's PB Ratio compare to its peers?

ITCI PB Ratio vs Peers
The above table shows the PB ratio for ITCI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average11.7x
RVNC Revance Therapeutics
ROIV Roivant Sciences
PRGO Perrigo
TLRY Tilray Brands
ITCI Intra-Cellular Therapies

Price-To-Book vs Peers: ITCI is good value based on its Price-To-Book Ratio (6.9x) compared to the peer average (11.7x).

Price to Earnings Ratio vs Industry

How does ITCI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: ITCI is expensive based on its Price-To-Book Ratio (6.9x) compared to the US Pharmaceuticals industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is ITCI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ITCI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ITCI's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ITCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ITCI ($57.9) is trading below our estimate of fair value ($367.64)

Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score


Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ITCI is expected to become profitable in the next 3 years.

Revenue vs Market: ITCI's revenue (44.6% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: ITCI's revenue (44.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ITCI's Return on Equity is forecast to be low in 3 years time (19.1%).

Discover growth companies

Past Performance

How has Intra-Cellular Therapies performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ITCI is currently unprofitable.

Growing Profit Margin: ITCI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.

Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).

Return on Equity

High ROE: ITCI has a negative Return on Equity (-38.29%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Intra-Cellular Therapies's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ITCI's short term assets ($848.3M) exceed its short term liabilities ($59.1M).

Long Term Liabilities: ITCI's short term assets ($848.3M) exceed its long term liabilities ($16.8M).

Debt to Equity History and Analysis

Debt Level: ITCI is debt free.

Reducing Debt: ITCI had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ITCI has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Sharon Mates (68 yo)





Dr. Sharon Mates, Ph D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...

CEO Compensation Analysis

Compensation vs Market: Sharon's total compensation ($USD7.25M) is about average for companies of similar size in the US market ($USD8.23M).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ITCI's management team is considered experienced (3.8 years average tenure).

Board Members

Experienced Board: ITCI's board of directors are considered experienced (8.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.

Top Shareholders

Company Information

Intra-Cellular Therapies, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Intra-Cellular Therapies, Inc.
  • Ticker: ITCI
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.461b
  • Shares outstanding: 94.32m
  • Website:

Number of Employees


  • Intra-Cellular Therapies, Inc.
  • 430 East 29th Street
  • New York
  • New York
  • 10016
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.